Suppressions of metastatic breast cancer invasion and metastasis to brain/cross talk HER2/ERK1/2/MMP-9 signaling pathway


American Journal of BioMedicine  Volume 2, Issue 11, pages1197-1209 November 2014

Yu-Chun Lin ; Dong-Qing Chin;  Eva Wang; Hao Cheng 


Understanding the molecular pathways that contribute to the development of metastatic breast cancer invasion and metastasis to brain is needed to improve the clinical utility of novel agents, and to predict the success of targeted personalized therapy based on tumor-specific mutations. Little is known about the clinical significance of HER2/ERK1/2/MMP-9 signaling pathway in breast cancer. We performed Global exon array to study the expression of ERK1/2/MMP-9 signaling pathway in metastatic breast cancer to brain, compared its expression in primary breast cancer and breast cancers metastatic to other organs, and validated the findings by RT-PCR. Immunohistochemistry was performed to study the expression and localization of ERK1/2/MMP-9 proteins in primary and metastatic breast cancer tissues and breast cancer cell lines. We performed matrigel invasion, transendothelial migration and membrane potential assays in established lines of normal breast cells.

Keywords: Breast cancer; ERK1/2/MMP-9; RT-PCR; Metastatic breast cancer;

Limited Access               HTML                 Full Text-PDF                Feedback


1. Ouadid-Ahidouch H, Ahidouch A. K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol 2008;221: 1–6. [PubMed]

2. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22(17):3608-3617. [PubMed]

3. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44(5):1913-1918. [PubMed]

4. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67(9):4190-4198. [PubMed]

5. Benz CC, O'Hagan RC, Richter B, et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513–1525. [PubMed]

6. Sontheimer H. Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol 2004; 29(1):61-71. [PubMed]

7. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737–744. [PubMed]

8. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648. [PubMed]

9. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 127a. [PubMed]

10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 from metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 11: 783–792. [CrossRef]

11. Esteva FJ, Sahin AA, Cristofanilli M, et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002; 12: 319–328. [PubMed]

12. Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res and Treat 2000; 62: 211. [PubMed]

13. Danielson AJ,Yousif NG; Wang DG, Maltzman AF, Johnston HG, Gomez AS, Lee H. Letrozole versus anastrozole in postmenopausal women with chemotherapy-refractory negative HER-2 metastatic breast cancer: a randomised, multicentre, open-label, non-inferiority phase 3 study. American Journal of BioMedicine 2014;4:440–431. [Abstract/Full-Text]

14. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life 2000; Sci 57: 5–15. [PubMed/NCBI]

16. Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011;108: 4852–4857.

17.  KhanS, Shukla S,  Sinha S. et al. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. The International Journal of Biochemistry & Cell Biology 2015;58: 1–16. [Abstract/Full-Text]

18. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869–10874. [PubMed]

19. Ivanov SV, Panaccione A, Nonaka D, et al. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer 2013;109: 444–451. [PubMed/NCBI]

20. Chang H, Mohabir N, Done S, Hamel PA. Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer. J Clin Pathol 2009;62: 908–914. [PubMed]

21. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27: 1160–1167. [PubMed]

22. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer 2011;11: 792–804. [PubMed]

23. Yousif NG, Al-Amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 2011 Oct 14;11:62. [PubMed]

24. Cedar H, Bergman Y. Programming of DNA methylation patterns. Annu Rev Biochem 2012;81: 97–117. [PubMed]

25. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71–96. [PubMed/NCB]

Print Friendly, PDF & Email